The ATTRibute-CM Trial
September 4, 2024 | Julian Gillmore and C. Michael Gibson discuss the efficacy of acoramidis for patients with transthyretin amyloid cardiomyopathy. |
TCTMD Talking Points
Off
2024-09-04T14:00:00Z